038530.Kq
The company operates in the drug retailing industry, generating revenue primarily through the sale of pharmaceuticals and related health products.
Business. The company operates in the drug retailing industry, generating revenue primarily through the sale of pharmaceuticals and related health products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the drug retailing industry, generating revenue primarily through the sale of pharmaceuticals and related health products.
The company maintains a strong liquidity position, with a current ratio of 5.2 and cash and equivalents amounting to KRW 30,676,903,770. This liquidity is supported by a low debt-to-equity ratio of 0.01, indicating minimal reliance on debt financing. However, the company reported a net loss of KRW 3,199,580,390, and a negative return on equity of -6.01%, suggesting poor profitability and capital efficiency.
Profitability metrics show significant underperformance relative to industry norms. The company's return on assets of -2.69% indicates that it is not generating returns sufficient to cover its asset base. Additionally, the operating margin, calculated as operating income of KRW 1,510,458,850 on revenue of KRW 87,311,777,140, is weak at 1.73%, which is likely below the industry median for drug retailers.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic fluctuations and regulatory changes. The absence of segment or geographic breakdown in the financial data limits the ability to assess risk distribution.
The company's growth trajectory appears to be constrained. With a net loss in the most recent period and a negative free cash flow of KRW -4,227,801,660, the company is not generating sufficient cash to fund operations and growth initiatives. The capital expenditure of KRW -98,539,130 further suggests limited investment in future capacity.
Risk factors include the company's negative net income and weak profitability, which could lead to increased financial pressure. The low dilution risk is supported by the absence of immediate filing-based flags, and the company has not issued additional shares recently. However, the negative free cash flow and low operating cash flow relative to capital expenditures may necessitate future financing, potentially leading to dilution.
Recent events include the filing of the latest financial report, which disclosed the net loss and weak profitability. No significant regulatory or operational events were reported in the latest filings. The company's financial health is closely tied to its ability to improve profitability and manage cash flow effectively.
- The company has strong liquidity but is currently unprofitable, with a net loss and negative return on equity.
- The company's profitability metrics are significantly below industry norms, indicating poor capital efficiency.
- The company's revenue is concentrated in a single segment, increasing exposure to regional and regulatory risks.
- The company is not generating sufficient free cash flow to support operations and growth, which may necessitate future financing.
- The company has low dilution risk in the near term, but its financial position may require additional capital in the future.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- 038530.KQ Market data — financials · 2026-05-26